Somatostatin analog treatment of a cervical thoracic duct fistula.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12203809.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Reoperation for recurrent thyroid cancer poses an increased risk of complications, including thoracic duct fistula. Treatment of this complication is controversial. A survey of thoracic literature reports the use of somatostatin analog, whereas no cases have reported the use of this therapy in cases arising from neck dissection. We report a 16-year-old girl with recurrent papillary thyroid cancer who had a persistent lymphatic-cutaneous fistula develop after repeat modified left neck dissection. Despite conservative management, drainage persisted for 2 months. A regimen was begun that included TPN and injections of a somatostatin analog. Treatment with a somatostatin analog resulted in an immediate attenuation of drainage and subsequent closure of the fistula after 16 days of treatment. The use of somatostatin analog can increase the success of conservative management of thoracic duct fistulae.
Medical subject headings
- Fistula
- Gastrointestinal Agents
- Lymph
- Octreotide
- Thoracic Duct